Innovation not only brings improved treatments to address large, unmet medical needs but can also improve access for underserved patient populations. PhotoPharmics today announced its intent to leverage its Breakthrough Device designation, CMS’s MCIT rule, and global delivery channels to deliver its treatments for Parkinson’s and neurodegenerative diseases to individuals regardless of their location or income.
The strength of the Company’s phase 2 data encouraged FDA to grant Breakthrough Device designation (details here) for its home-based, non-invasive therapeutic device in Parkinson’s. This designation speeds FDA’s review process for devices that provide for more effective treatment for life-threatening or irreversibly debilitating diseases.
Phase 3 Trial Aims to Establish Non-Motor Improvement in Parkinson’s PhotoPharmics and University...
FDA Grants Breakthrough Designation for Non-Invasive Phototherapy Device in Parkinson’s Disease...
View the full release on EIN Newswire Largest Phototherapy Trial for Parkinson’s Disease...
We wanted to take a closer look at the effects of good nutrition on people with Parkinson’s disease. And thankfully for us there was a lot of great information out there. The effects of a good diet on Parkinson’s disease is a subject that has been covered extensively by researchers, scientists and advocacy groups. Read more >
One of the things we love most about this time of year is that it allows us to start getting outside again into the warm and sunny weather. But are there any benefits to being outside for people with Parkinson’s? Read more >
We at PhotoPharmics are passionate about representing the Parkinson’s community in an effort to raise awareness. In a recent survey, PhotoPharmics discovered a large percentage of people are waiting with great eagerness for breakthroughs that will improve the standard of care for people with Parkinson’s. Read more >